\n\n\n\n\t\t\n\t\t\tLab21\n\t\t\thttp://www.lab-21.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tLab21 supports healthcare providers and the pharmaceutical and biotechnology industries with technically advanced testing services.
The Lab21 team\u2019s experience and know-how is coupled with a...More»
Lab21 supports healthcare providers and the pharmaceutical and biotechnology industries with technically advanced testing services.
The Lab21 team\u2019s experience and know-how is coupled with a rapidly growing portfolio of molecular and viral diagnostics, plus pharmacogenetic and patient profiling tests, which all use cutting-edge technology. This unique combination adds value to early stage drug development, clinical trials and regulatory processes in pharmaceutical industry \u2013 and directly to clinicians or healthcare providers as they treat and monitor patients.
As we move towards truly personalised healthcare, the Lab21 team can contribute today - delivering high-quality information on drugs and patients that provides real clinical insight.
Lab21 supports healthcare providers and the pharmaceutical and biotechnology industries with technically advanced testing services.«Less
Overview
\n\t\t\t\tLocation: \tFareham, Hampshire, United Kingdom\n
\n\t\t\t\tIndustry: Other Healthcare
\n\t\t\t\tEmployees: 46
\n\t\t\t\tTags:\n\t\t\t\tviral,\n\t\t\t\tlab 21,\n\t\t\t\tactitest,\n\t\t\t\tpharmacogenetic,\n\t\t\t\tHealthcare,\n\t\t\t\tfibrotest,\n\t\t\t\tlab-21,\n\t\t\t\tdiagnostics,\n\t\t\t\tmolecular,\n\t\t\t\tantiviral\n\t\t\t\t
\n\t\t\tFinancials
\n\t\t\t\tLatest Funding: Series B - $3.24M (12/2008)
\n\t\t\tMarket
\n\n\t\t\t\tRelated Companies:\n\t\t\t\t\tTobira Pharmaceuticals,\n\t\t\t\t\tPointCare Technologies,\n\t\t\t\t\tCelera Diagnostics,\n\t\t\t\t\tHelixis\n\t\t\t\t
\n\t\t\t